National Institute for Public Health and the Environment (RIVM), Centre for Safety of Substances and Products (VSP), Bilthoven, the Netherlands.
National Institute for Public Health and the Environment (RIVM), Centre for Safety of Substances and Products (VSP), Bilthoven, the Netherlands.
Regul Toxicol Pharmacol. 2022 Oct;134:105235. doi: 10.1016/j.yrtph.2022.105235. Epub 2022 Jul 30.
The concept of the Maximum Tolerated Dose (MTD) was introduced in the seventies for carcinogenicity testing and was defined as the highest dose inducing clear toxicity, but not mortality by causes other than cancer. As estimation of the MTD in a carcinogenicity study, the highest dose that causes a 10% decrease in body weight compared to control animals over the course of a 90-day study, was formulated as a suitable criterion. This criterion was not seen as indicator of excessive toxicity but as a means to avoid false negative outcomes in a carcinogenicity study, as tumor formation may be reduced when body weight is significantly decreased. The body weight-based MTD criterion, however, turned up in carcinogenicity test guidelines and guidance (e.g., from OECD) as the highest dose that causes a 10% decrease in body weight gain relative to controls. Moreover, the 10% decrease in body weight gain criterion for MTD also ended up in test guidelines and guidances for toxicity endpoints other than carcinogenicity, so outside the context it was intended for. A 10% decrease in body weight gain relative to controls is however not a biologically relevant effect as it corresponds to less than 3% body weight reduction relative to controls in a 90-day study, which is within the normal variation in body weight. It therefore should certainly not be considered as a condition of excessive toxicity. Using the 10% lower weight gain criterion and incorrectly associating it with excessive toxicity has major implications for top dose selection in regulatory safety studies, resulting in tests performed at doses too low to elicit toxicity. This negatively impacts the reliability of studies and their regulatory usability; moreover, it results in a waste of experimental animals, which is ethically highly undesirable. Hence, our plea is to remove this MTD criterion for top dose selection in test guidelines and guidances for toxicity endpoints other than carcinogenicity and to reinstall the original 10% decrease in body weight criterion in test guidelines and guidances for carcinogenicity.
最大耐受剂量(MTD)的概念于 70 年代在致癌性测试中引入,其定义为引起明显毒性但不引起癌症以外其他原因导致死亡的最高剂量。作为致癌性研究中 MTD 的估计,最高剂量是在 90 天研究过程中相对于对照动物体重下降 10%的剂量,这被认为是一个合适的标准。该标准不被视为毒性过高的指标,而是作为避免致癌性研究中假阴性结果的一种手段,因为当体重显著下降时,肿瘤形成可能会减少。然而,基于体重的 MTD 标准出现在致癌性测试指南和指导(例如来自 OECD)中,作为导致相对于对照动物体重增加下降 10%的最高剂量。此外,MTD 的体重减轻 10%标准也出现在致癌性以外的毒性终点的测试指南和指导中,因此超出了其预期的应用范围。相对于对照动物体重增加下降 10%并不是一个具有生物学意义的效应,因为它相当于相对于 90 天研究中的对照动物体重减少不到 3%,这在体重的正常变化范围内。因此,它肯定不应被视为毒性过高的条件。使用体重减轻 10%的标准,并错误地将其与毒性过高联系起来,对监管安全研究中的最高剂量选择有重大影响,导致在太低的剂量下进行测试而无法引起毒性。这会降低研究的可靠性及其监管可用性;此外,还会导致实验动物的浪费,这在伦理上是非常不可取的。因此,我们恳请在致癌性以外的毒性终点的测试指南和指导中删除该 MTD 最高剂量选择标准,并在致癌性测试指南和指导中重新安装体重减轻 10%的原始标准。